Robert A. Seder

New Capabilities

Leading MAD21-101 antibody research and monoclonal antibody trials

NIH researchers discovered a new class of antibodies that attack malaria parasites at a never-before-targeted site. The antibody MAD21-101 protected four out of five mice from infection and works differently than existing vaccines, binding to a cryptic protein fragment exposed only after the parasite undergoes a specific chemical transformation called pyroglutamylation. The breakthrough opens a fresh avenue in the decades-long hunt for a highly effective malaria vaccine.

Updated Jan 7